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1INTRODUCTION
Diastolic Heart failure (DHF) is characterized by signs and /or
symptoms of heart failure in presence of a normal ejection fraction
(EF).Prognosis  of  DHF  is  as  poor  as  that  of  systolic  failure,  and  the
number of cases is likely to increase within aging populations. Heart
failure with normal systolic function has been equated to diastolic heart
failure (DHF). DHF appears to be quite common in the elderly,
especially in elderly women with hypertension. Recent epidemiologic
studies suggest that 30%-50% of patients with heart failure may have
DHF. Morbidity for DHF is comparable to that of heart failure with left
ventricular systolic dysfunction. Both groups of patients have similar
rates of recurrent hospitalization and cost of care. Long-term mortality
also appears to be similar in the two groups of patients. With the aging
of the population, the number of patients with DHF will continue to rise
and are likely to contribute significantly to the burden of disease caused
by heart failure. Unfortunately, as yet, no reliable definition has been
found for DHF. Currently the diagnosis of DHF is often made by
exclusion, and treatment is empirical and unsatisfactory because of the
lack of large-scale, randomized, controlled trials in this area; however,
several large and other smaller trials are currently in progress that will
hopefully provide some answers.
2AIM OF THE STUDY
? To assess the the prevalence of diastolic heart failure in elderly
with congestive heart failure
? To study the association with demographic factors like
1) Age
2) Sex
and comorbid conditions  like
1) Hypertension
2) Diabetes mellitus
3) Coronary artery disease
4) Atrial Fibrillation
5) Chronic kidney disease
6) Hypothyroidism
7) Obesity
3MATERIALS  AND  METHODS
 STUDY CENTRE:
Department of Geriatric medicine, Madras Medical College &
Government General Hospital Chennai-600003
STUDY DESIGN:
Cross sectional, descriptive study
SAMPLE SIZE:
Ninety
STUDY DURATION:
August 2008 - September 2011
SELECTION OF PATIENTS:
INCLUSION CRITERIA:
90  elderly  patients  age  ?60  admitted  with  typical  signs  and
symptoms of congestive heart failure are included in this study.
4EXCLUSION CRITERIA:
Patients with evidence of
1) Congenital heart disease,
2) Valvular heart disease,
3) Pericardial disease and
4) High output heart failure (severe anemia, Thyrotoxicosis,
AV fistula) are excluded from this study
METHODOLOGY:
The study enrolled 90 patients admitted in Govt general hospital
with  features  of congestive heart failure according to Framingham
criteria. Age group selected for this study are ?60yrs, individuals were
characterized by detailed medical history, clinical examination,
ECG,Chest Xray,echocardiography,and following lab tests:Hb,blood
sugar,urea,serum creatinine,serum electrolytes,serum albumin and LDL.
DHF was defined as
 (1) Clinical signs of heart failure,
(2) Ejection fraction ?50,
(3) Echocardiographic findings of diastolic dysfunction.
1. Calculation of Ejection Fraction by two methods
a) Teicholtz  formula
b) Simpson’s rule
52) Dimension
 a) LA b) LV c)IVS d)RA e)RV
3) Doppler Echocardiographic  Finding Of diastolic Dysfuntion
TRANS MITRAL FLOW
a) Assessment of Transmitral flow velocity during early
diastole(E) and during atrial contraction(A)
b)  E/A
c) Deceleration Time(DT)
d) Isovolumetric relaxation time(IVRT)
PULMONARY VENOUS FLOW
a) Systolic  velocity(S)
b) Diastolic velocity(D)
c) Atrium to pulmonary veins during atrial contraction(AR)
4) Pulmonary Hypertension
5) Regional wall motion abnormality
6) Right ventricular Function
7) Valvular heart disease
ANALYSIS
Data analysed using statistical package-SPSS Software
6REVIEW OF LITERATURE
 Cardiovascular Changes Related to Aging
Knowledge of cardiovascular changes that occur with aging are
important for several reasons:
? Recognition of these changes allow us to better distinguish
normal cardiovascular aging from disease states in elderly.
? Manifestation of various cardiovascular disease vary between
young and old patient, e.g. hypertension manifest as elevated
diastolic pressure in young and systolic in elderly.
? Ability for an individual to compensate for their cardiovascular
illness may be age dependent and thus an elderly patient may be
more symptomatic for any burden of disease.
? Response to appropriate cardiovascular therapy may be age
dependent, such as Beta adrenoreceptor blockade.
There have not been clear cut distinction between when an age
related phenomenon becomes a disease related phenomenon, e.g, Left
ventricular mass increase with increasing age and increasing left
ventricular mass predicts future cardiovascular morbidity and mortality.
7? Age-related changes in the cardiovascular system parallel age-
related changes elsewhere in the body. However, age-related
changes in a single organ or group of organs, such as the brain,
lungs, or kidneys, may predominate, while, other organs remain
unaffected.
? Age-related changes in the cardiovascular system are specific and
enumerable. First, elderly hearts experience myocyte hypertrophy
along with an increase in the connective tissue matrix1.  On  the
cellular level, total number of myocytes decreases and remaining
myocytes hypertrophy2. The weight of the heart increases 1.5
g/year between 30 and 90 years of age because of this
hypertrophy and connective tissue deposition3-4.
?  With aging, ventricular chamber dimensions decrease with septal
hypertrophy because of increased ventricular septal thickness and
decreased base-to-apex dimensions. The sigmoid septum of aging
is another morphologic manifestation of the senescent heart
resulting from the reduction in the ventricular cavity size and
rightward shift of the ascending aorta5. Although not
hemodynamically significant, this curved septum simulates
asymmetric hypertrophic cardiomyopathy.
8? Despite structural changes, systolic function of the heart at rest
remains essentially normal. However, alterations that impair peak
systolic function do occur at the subcellular level of myocardial
function. These include availability of energy stores, intracellular
calcium handling, and transmembrane action potential6.
AGE-RELATED CHANGES IN CARDIAC ANATOMY
MYOCARDIUM Increased heart weight, LV mass, LV wall
thickness Increased myocyte size, decreased
myocyte number Fibrosis with deposition of less
distensible form of collagen.
CHAMBERS Decreased LV cavity size, shortened long axis
Rightward shift and dilatation of the aorta
Dilatation of left atrium, senile septum.
VALVES Calcific and fatty degeneration of valve leaflets
and annuli
CORONARY
ARTERIES
Atherosclerosis Dilation, tortuosity, and
Monckeberg’s calcific arteriosclerosis.
CONDUCTION
SYSTEM
Fibrosis of atrioventricular node and left
anterior fascicle Loss of specialized cells and
fibers.
9AGE-RELATED CHANGES IN CARDIOVASCULAR
PHYSIOLOGY
VASCULAR IMPEDANCE
INCREASES IN LARGE AND
MEDIUM-SIZE ARTERIES
Pulse wave velocity and pulse
pressure increases Systolic blood
pressure increases Impaired
endothelial function.
MYOCARDIAL
RELAXATION DECREASES
Diastolic dysfunction develops
Peak EF maintained by a larger
diastolic volume Cardiac output
and stroke volume are preserved at
rest.
ELECTRICAL
CONDUCTION AND HEART
RATE RESPONSE TO
STIMULI IS IMPAIRED
PR,  QRS,  and  QT  are  prolonged
Peak exercise HR declines
Sensitivity to Beta agonists is
decreased Reactivity to
chemoreceptors and baroreceptors
is diminished.
INTEGRATED
PERFORMANCE DURING
CARDIOVASCULAR
EXERCISE IS IMPAIRED
Decrease peripheral muscle mass;
increased adipose tissue
Diminished respiratory capacity
Diminished VO2 max reserves
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? In contrast to systolic function, which is preserved at rest,
diastolic function is impaired. Connective tissue matrix becomes
replaced with a less distensible form of collagen. This causes
greater stiffness of the senescent heart, requiring greater filling
pressures to adapt via the Frank-Starling mechanism9.
? Progressive cellular disarray, myocyte asynchrony, and abnormal
calcium handling further affect the compliance and filling
parameters during diastole. From a study of senescent animal
models, the most predictable change in cardiac muscle function is
longer duration of relaxation. This impaired relaxation with
senescence is attributable to slower intracellular handling of
calcium and longer action potentials, in addition to the stiffness
from altered collagen. Echocardiographic Doppler studies in
humans confirm prolonged relaxation and slower early diastolic
filling with aging10.
?  However, end-systolic volumes are usually maintained by
augmentation of late diastolic filling evidenced by exaggerated A
wave and altered E:A ratio through the mitral valve11. Diastolic
function of the aging heart may be worsened by coexisting
structural changes, such as mitral or aortic valvular disease,
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hypertension, atrial arrhythmias, or senile amyloidosis, which
further alter hemodynamic conditions.
? Age-related changes in the arterial system begin in the 30s and
accelerate through midlife. Increased collagen deposition and
weakened vascular elastin result in altered elasticity,
distensibility, and dilatation. These changes, particularly in the
intima, appear to resemble those that occur during
atherosclerosis12-13. Within the vascular media, there is
progressive growth of smooth muscle, as well as deposition of
lipids and calcium in the elastic lamella. Stiffening of the central
arteries results in higher pulse wave velocities and augmentation
in systolic arterial pressure, and whereas the lower elasticity
results in a diminished contribution of arterial recoil to forward
arterial perfusion. As arterial distensibility decreases, the speed of
travel  of  the  pulse  along  an  arterial  segment,  referred  to  as  the
pulse wave velocity, increases. The forward cardiac ejection wave
travels through central compliance arteries until it meets forward
resistance. The pulse wave is then reflected (reflection wave),
where it sums with continuing forward cardiac ejection increasing
systolic pressures. Less compliant vasculature returns the
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reflection wave sooner, making a greater contribution to systolic
pressure. Cyclic fatiguing and elastase activity also result in a
reduction and fragmentation of vascular elastin14.
? Vascular remodeling therefore takes place and results in dilatation
and elongation of the aorta and major arteries. These changes are
accompanied by impaired endothelial function owing to reduced
prostacyclin production by cells which remain. With age, the
endothelium undergoes apoptosis, progressive irregularity in cell
size and shape, and increased multinucleated giant cells.
Endothelial-dependent responses to agonists such as acetylcholine
are therefore impaired15-16.
? Age-related changes in the conduction system result from
apoptosis and the deposition of collagenous and fatty tissue. Fat
accumulates around the sinoatrial node, sometimes producing
partial or complete separation of the node from the atrial
musculature. There is also a pronounced decrease in the number
of pacemaker cells in the sinoatrial node beginning at age 60.
At age 75, less than 10% of the cell number found in the young
adult remains.
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? Calcification of the atrioventricular node and left and right bundle
branches also occur. Thus, older patients often have modest
increases in electrocardiographic PR and QT intervals, increased
QRS duration and bundle branch blocks, and decreased T-wave
amplitude17. The maximum predicted heart rate (HR) in an
octogenarian is 30 beats per minute lower than it was at age 50,
and HR in older individuals is also less responsive to Beta-
adrenergic stimulation.
? In the Framingham cohort, variability in RR intervals declines by
38% between age 40 and 70, reflecting the lesser contribution of
autonomic tone to cardiac function with aging18. Altered
autonomic regulation is also demonstrated by reduced heart rate
variability (HRV) to head-up tilt testing and impaired
baroreflex19. The Framingham study demonstrated the gradual
increase in the prevalence of atrial fibrillation in the population
between age 50 and 8020. In addition, there is an increase in
ambient rate of premature atrial and ventricular contractions as
evidenced by holter monitors in healthy adults. Short runs of
supraventricular tachycardia occur in up to 33% of healthy
individuals over age 6021.
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? Aerobic capacity (VO2 max) declines with normal aging due to
diminished cardiac reserve. Age-related changes in heart function
must be differentiated from those resulting from a sedentary
lifestyle or other disease processes. Many older patients become
inactive, both physically and mentally, which accelerates
deterioration and loss of function22. Early studies found a steady
decline in overall cardiovascular performance with aging as
judged from exercise training23.
DEFINITION
Heart failure is defined as the pathologic state in which the heart
is unable to pump blood at a rate required by the metabolizing tissues or
can do so only with an elevated filling pressure. Inability of the heart to
pump blood sufficiently to meet the needs of the body tissues may be
attributable to the inability of the LV to fill(diastolic performance) or
eject(systolic performance).When the heart failure is associated with a
reduced EF, the pathologic state may be called systolic heart failure. In
contrast, when the heart failure is associated with diastolic dysfunction
in the absence of a reduced EF, the pathologic state is diastolic heart
failure.
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EPIDEMIOLOGY
Thirteen epidemiological studies have defined the prevalence of
DHF in various HF populations and have documented a prevalence of
50 to 55 percent. [10] [14] [15] [16] Importantly, the prevalence of DHF
among patients with HF varies dramatically with age and gender. The
prevalence of HF increases with age and is similar in men and women .
The prevalence of HF with a depressed EF increases with age but is
more common in men than in women at any age  whereas the prevalence
of DHF increases even more dramatically with age (more than HF with
a reduced EF) and is much more common in women than in men at any
age . More data are needed concerning variation in the prevalence of
DHF in different regional and ethnic groups.
NATURAL HISTORY
MORTALITY
Most large contemporary studies have now suggested that the
mortality for DHF is similar to that of HF with a reduced EF. [25] [29] [30]
Differences in survival between the two forms of HF are minimal.
Although  survival  has  improved  over  time  for  patients  with  HF with  a
reduced EF, it has not changed for patients with DHF.[24] In the Digitalis
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Investigation Group (DIG) study, which included patients with DHF,[25]
the cause of death was somewhat different in patients with DHF, in
whom deaths caused by non cardiovascular and non-HF cardiovascular
mechanisms were more frequent.
MORBIDITY
Patients with DHF have comparable morbidity to those with HF
with a reduced EF, with similar or minimal differences in HF
readmission rates.[30] Rates of progressive functional decline after
an admission for HF are also similar in patients with preserved or
reduced EF.[26]
CAUSES OF DIASTOLIC DYSFUNCTION AND HEART
FAILURE
Common causes
Cardiac ischemia
Hypertension
Aging
Obesity
Aortic stenosis
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Uncommon causes
Myocardial disorders
Myocardial diseases
Infiltrative disease (e.g., amyloidosis, sarcoidosis, fatty
infiltration)
Noninfiltrative diseases (e.g., idiopathic and hypertrophic
cardiomyopathy)
Endomyocardial diseases
Hypereosinophilic syndrome
Storage diseases
Glycogen storage disease
Hemochromatosis
CLINICAL FEATURES
Patients with DHF were shown to have similar pathophysiological
characteristics compared with HF patients with a reduced EF including
severely reduced exercise capacity, neuroendocrine activation, and
impaired quality of life despite normal EF, normal left ventricular (LV)
volume, and an increased LV mass-to-volume ratio.[27]
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Clinical Features of  Diastolic Heart Failure
Parameter Features
Framingham criteria for diagnosis of heart failure[*]
Major criteria Paroxysmal nocturnal dyspnea or orthopnea
Jugular venous distention (or CVP > 16 mm Hg)
Rales or acute pulmonary edema
Cardiomegaly
Hepatojugular reflex
Response to diuretic (weight loss >4.5 kg in 5 days)
Minor criteria Ankle edema
Nocturnal cough
Exertional dyspnea
Pleural effusion
Vital capacity < two thirds of normal
Hepatomegaly
Tachycardia (>120 bpm)
Demographic features Elderly; female > male
Underlying CV disease Hypertension, coronary disease, diabetes, atrial fibrillation
Comorbidities Obesity, renal dysfunction
Doppler echocardiography results
LV size Normal to ? (small subset with?)
LV mass LVH common but frequently absent; ? relative wall
thickness (> 0.45)
Left atrium Enlarged
Diastolic dysfunction Grade I-IV (? diastolic dysfunction severity, BP, volume
status)
Other features PH, wall motion abnormality, RV enlargement
Pertinent negatives Rule out valve disease, pericardial disease, ASD
BNP or NT-proBNP ? but HFnlEF < HFrEF
Exercise testing ? VO2 peak
Exaggerated hypertensive response in many
Chronotropic incompetence in subset
Chest radiogram Similar to HFrEF, cardiomegaly, pulmonary venous
hypertension, edema, pleural effusion
Electrocardiogram Variable
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RISK FACTORS
Patients  with  DHF  are  generally  older  than  age  65  years,  with
many older than 80, and are predominantly women (60 to 70 percent).
A history of hypertension is present in most (60 to 80 percent) and may
have developed only later in life. Obesity is seen in 30 to 50 percent of
patients, diabetes in 30 to 50 percent, and atrial fibrillation in up to 20 to
40 percent. The prevalence of renal disease is high and similar to that
noted in patients with HF and a reduced EF. The reported medications at
diagnosis in patients with DHF have included diuretics, digoxin,
angiotensin-converting enzyme (ACE) inhibitors, beta blockers, calcium
channel blockers and various other vasodilators, and antihypertensive
and antiarrhythmic drugs. [25] [29] [30] [16] The reported prevalence of
coronary artery disease varies widely.[29]
AGING
Although cardiovascular disease may contribute to diastolic
dysfunction in older people, studies have also suggested that diastolic
function deteriorates with normal aging.[30] The speed of LV relaxation
declines with age in men and women, even in the absence of
cardiovascular disease.[30] It also appears that vascular, LV systolic, and
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LV diastolic stiffness increase with aging.  Increases in vascular stiffness
have  been  shown  to  be  related  to  effort  intolerance  in  patients  with
DHF. Structural cardiac changes with aging (e.g., increased
cardiomyocyte size, increased apoptosis with decreased myocyte
number, altered growth factor regulation, focal collagen deposition) and
functional changes at the cellular level involving blunted beta-
adrenergic responsiveness, excitation-contraction coupling, and altered
calcium-handling proteins may contribute to diastolic dysfunction with
normal aging. Some studies have suggested that prolonged, sustained
endurance training may preserve LV compliance with aging and help
prevent HF in the elderly.[18]
GENDER
Along with age, female gender is a potent risk factor for DHF.
Indeed, there appears to be important age-gender interactions, such that
the prevalence of DHF increases more sharply with age in women than
the prevalence of HF with a reduced EF . The reasons for the female
predominance in DHF are not entirely clear, but women have higher
vascular and LV systolic and diastolic stiffness than men, and vascular
and ventricular stiffness increases more dramatically with age in
21
women.[30] Emerging evidence of unique coronary vascular functional
changes in women may play a role in DHF pathophysiology.
HYPERTENSION
Hypertension is the most commonly associated cardiac condition
in  patients  with  DHF.  Chronically  increased  blood  pressure  is  an
important stimulus for cardiac structural remodeling and functional
changes. The resultant hypertensive heart disease is characterized by LV
hypertrophy (LVH), increasing vascular and ventricular systolic
stiffness, impaired relaxation, and increased diastolic stiffness, all
factors linked to the pathogenesis of DHF. In the presence of
hypertensive heart disease, ischemia produces exaggerated increases in
filling pressures, and hypertensive and ischemic heart disease are often
present in combination in patients with DHF. Elucidating which factors
mediate transition to DHF in persons with hypertensive heart disease is
an area of active investigation. [29-30]
CORONARY ARTERY DISEASE.
The reported prevalence of coronary artery disease or myocardial
ischemia in patients with DHF varies widely. [29-30] Although acute
ischemia is known to cause diastolic dysfunction , the role of coronary
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artery disease and ischemia in contributing to chronic diastolic
dysfunction and symptoms in patients with DHF remains speculative.
Despite uncertainty regarding the role of ischemia in the
pathophysiology of DHF and a lack of data documenting that
revascularization improves outcomes in patients with DHF, HF
management guidelines recommend revascularization in those DHF
patients in whom ischemia is felt to contribute to diastolic dysfunction.
[26-27] Importantly, emerging evidence suggests that unique coronary
vascular functional changes are present in women.
ATRIAL FIBRILLATION AND OTHER RHYTHM
DISTURBANCES
Atrial fibrillation is recognized as a frequent precipitant of acute
decompensation in patients with DHF.  Whereas atrial fibrillation may
cause decompensated HF in patients with diastolic dysfunction, diastolic
dysfunction (in the absence of HF) is also a risk factor for atrial
fibrillation. Thus, diastolic dysfunction, atrial fibrillation, and DHF are
common and related conditions that probably share common pathogenic
mechanisms in the elderly. The prevalence of ventricular arrhythmias in
DHF is poorly defined. Although tachycardia caused by atrial
arrhythmias is a recognized precipitant of acute decompensation in
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DHF, bradycardia and adverse atrioventricular timing caused by first-
degree heart block may also adversely affect LV filling in some patients.
OBESITY
Obesity is associated with an increased risk for HF. In general,
patients  with  DHF  are  more  often  obese  than  patients  with  HF  with  a
reduced EF, 29-30and the prevalence of diastolic dysfunction is increased
in obese persons. Increased adiposity not only imposes an adverse
hemodynamic load on the heart but is also a source of a large number of
biologically active peptide and nonpeptide mediators, many linked to
chronic inflammation by various pathways. Increased body mass index
(BMI) is a risk factor for hypertension, diabetes mellitus, coronary
artery disease, and atrial fibrillation, all of which are associated with
DHF. Studies using tissue Doppler imaging or invasive LV pressure
measurement have reported an association between diastolic
dysfunction, elevated filling pressures, and obesity.
DIABETES MELLITUS
Diabetes is a potent risk factor for HF, and the prevalence of
diabetes is similar in patients with HF and reduced or preserved EF,
suggesting that diabetes contributes to the pathophysiology of both
24
forms of HF. Although diabetes predisposes to coronary artery disease,
renal dysfunction, and hypertension, numerous direct effects of diabetes
and hyperglycemia on myocardial structure and function have been
described. The morphological changes in the diabetic heart include
myocyte hypertrophy, increased extracellular matrix (fibrosis), and
intramyocardial microangiopathy. Functional changes, which may
represent a continuum, include endothelial-dependent and endothelial-
independent microvascular dysfunction, impaired relaxation, and
increased passive diastolic stiffness and contractile dysfunction.
Mechanisms contributing to structural and functional coronary vascular
and myocardial changes are diverse and include metabolic disturbances,
activation of proinflammatory and profibrotic mediators, cardiac
autonomic neuropathy, and increases in advanced glycation end-
products (AGE), which promote increased collagen accumulation and
increased collagen stiffness. AGE accumulation may also play a role in
age-related cardiovascular stiffening.
RENAL DYSFUNCTION
The critical impact of renal function on morbidity and mortality
in HF is well established. Studies have shown no difference
between the severity of renal dysfunction in patients with reduced
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or preserved EF.29-30 Furthermore, the incidence of worsening renal
function during HF therapy is similar in patients with preserved or
reduced EF.Although the prevalence of renal vascular disease in HF has
been poorly delineated, it is probably high, and bilateral renal artery
stenosis with rapid-onset or flash pulmonary edema is a well-recognized
cause of DHF. Evaluation of the renal arteries should be considered
in patients presenting with the triad of hypertension, renal dysfunction,
and DHF.
RARER CAUSES OF DIASTOLIC HEART FAILURE
Hypertrophic cardiomyopathy, infiltrative cardiomyopathies such
as amyloidosis, valvular disease, and constrictive pericarditis should
always be considered in young patients with DHF or patients with other
suggestive features. However, these diseases account for a minority of
patients with DHF. Idiopathic restrictive cardiomyopathy in young
persons without the above mentioned factors may represent a distinct
group, particularly if a family history is present. However, the clinical
presentation and echocardiographic appearance in older persons with
DHF may be identical to those of patients previously labeled as having
restrictive cardiomyopathy. An important consideration in patients with
previous malignancy treated with mediastinal radiation is radiation heart
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disease. Radiation can cause pericardial and concomitant myocardial
damage, and outcomes after pericardiectomy are frequently poor
because of concomitant restrictive myocardial disease. Concomitant
valvular disease and premature coronary artery disease are also common
in patients with previous mediastinal radiation and may contribute to the
pathophysiology of DHF in patients with radiation heart disease.
 PATHOPHYSIOLOGY OF DIASTOLIC HEART FAILURE
Algorithm for pathophysiology of diastolic heart failure.
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          In the clinical definition most often used, diastole is delineated by
the onset of isovolumic relaxation and closure of the mitral valve.
Applying this definition, ventricular relaxation is included in diastole,
which is understandable since active myocardial relaxation influences
ventricular pressures during early and mid-diastole. Diastole is
traditionally divided into four phases,i.e. isovolumic relaxation, early
diastolic filling, diastasis and atrial contraction. In all phases, a
multitude of factors determines LV filling with a varying relative
importance. These factors overlap in time31, and are influenced by each
other, by LV systolic function, heart rate, and by the cardiac conduction
system. Their final combined effect is on the transmitral pressure
gradient, which actually determines LV filling.
Isovolumic relaxation
Myocardial relaxation requires dissolution of the force-generating
crossbridges between myosin and actin. Myocardial sarcomeres generate
force under the direct control of calcium32, and prompt relaxation
demands the reduction of myocyte cytosolic calcium to its
physiologically low concentrations. This is achieved by a sarcoplasmic
reticulum calcium transporting ATPase that pumps calcium ions against
a concentration gradient back into storage sites within the sarcoplasmic
reticulum.In addition, sodium–calcium exchangers and sarcolemmal
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calcium pump transport calcium outward across the sarcolemma. Since
myofilaments may sustain active cross bridge connections beyond the
time that cytosolic free calcium has been reduced to its diastolic
concentration in the normal myocardium, mechanical relaxation will be
limited  by  the  myofilaments  per  se,  not  the  calcium  exchange  rate.  In
failing human heart, both myofilaments and calcium exchange pumps
act more slowly, i.e. an attenuation of calcium sensitivity develops. The
relative timing of crossbridge dissociation and calcium uptake may alter
and the removal of calcium may become rate limiting, causing LV
relaxation to decelerate33. Since calcium reuptake is an energydependent
process, relaxation may thus become abnormal early in several cardiac
disease states; ischemia,hypertrophy and heart failure will all lead to
slowing of LV relaxation34-36.
 Early diastolic filling
Early rapid filling of the LV starts with the first reversal of the
atrioventricular pressure gradient opening the mitral valve and
accelerating the blood into the ventricle. An explosive period of filling
ensues during which the largest proportion (80–85%) of total LV filling
occurs under physiological conditions. Filling velocity reaches its
maximum when the atrioventricular pressure gradient reverses again,
although fluid inertia will cause LV filling to continue. Finally, LV
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filling decelerates to a minimum until a third pressure gradient reversal
occurs at the beginning of diastasis37. Thus, the instantaneous
atrioventricular pressure gradient determines flow during the rapid
filling phase. The acceleration of early flow will be determined by the
rate of ventricular relaxation and left atrial pressures resulting from
loading conditions and atrial and pulmonary vein compliance38.
 Diastasis and Atrial Contraction
Diastole further encompasses diastasis and the atrial contraction
phase. On a time scale, their duration mainly depends on heart rate and
on the duration of systole,and at normal heart rates, this will correspond
to  approximately  50%  of  the  total  duration  of  the  cardiac  cycle.  On  a
volume scale however, only the last 5–15% of ventricular filling occurs
during diastole. Once deceleration of early rapid filling flow is
complete, LV filling enters a phase during which only a small additional
volume is slowly added to the LV, accompanied by a very gradual rise
in LV pressure39. In young volunteers, only 6% of total LV filling
volume is added during diastasis in approximately 180ms, and presently,
mechanisms operating during diastasis are not considered important in
overall diastolic function.
The left atrium acts as a reservoir during systole, storing blood at
a certain pressure which is determined by left atrial compliance, blood
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that is subsequently supplied to the ventricle during diastole. The atrial
contraction has a booster effect on LV filling, contributing
approximately 15% of the total LV filling volume. The effectiveness of
the atrial contraction is dependent on LV compliance (i.e. atrial
afterload), but also atrial preload, heart rate, atrial contractility and atrial
geometry. Particularly at increased heart rates, during exercise, or in
case of impaired LV function, atrial contribution may be increased, thus
augmenting LV filling and, through the Frank–Starling mechanism,
increasing cardiac output40. Increase of atrial reservoir and pumping
capacity will act as a first mechanism in response to impairment of LV
filling in the failing heart. Eventually, left atrial dilatation and atrial
afterload mismatch will result in ineffective atrial systolic function,
rendering the atrium to a mere conduit for flow.
Diastolic heart failure
Conceptually, the causes of diastolic dysfunction may be
subdivided into a decrease in passive myocardial diastolic compliance,
and an impairment in active LV relaxation. A variety of myocardial and
pericardial disorders may provoke an upward shift of the diastolic
portion of the LV pressure–volume or pressure–dimension relation,
resulting in relatively large changes in LV diastolic pressures for
relatively small volume changes. It is the shift in LV pressure volume
relation that causes the symptoms of pulmonary congestion
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(i.e. dyspnea), first occurring during exercise, later also in rest. Patients
with diastolic dysfunc tion may be unable to normally augment stroke
volume e.g. during exercise, even in the setting of increased ventricular
filling pressure41.
          In systolic heart failure, a downward and rightward shift of the
end-systolic pressure-volume line indicates decreased contractile
function, which is the principal cause of reduced ejection fraction and
forward stroke volume. In primary diastolic heart failure, diastolic
pressure-volume relation (dashed line) shifts upward and to the left,
indicating a disproportionate and a greater increase in diastolic pressure
for any increase in diastolic volumes. If there is also a decrease in end-
diastolic volume, then a decrease in stroke volume also occurs
METHODS OF DIAGNOSING DIASTOLIC HEART FAILURE
Findings on Doppler Echocardiography
Comprehensive Doppler echocardiography is invaluable in the
evaluation of HF patients. Although other cardiovascular imaging
techniques may provide as good or even more accurate assessment of
cardiac structure or function, the widespread availability and
comprehensive functional information provided by echocardiography
make it the test of choice for patients with HF.
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LV Size
Most patients with DHF have normal chamber dimensions,
although a subset will have variable degrees of LV enlargement.[44]
LV Hypertrophy
Although DHF has been thought to occur primarily in patients
with LVH, studies that have carefully quantified LV mass report that
echocardiographic criteria for LVH are met in less than 50 percent of
patients.46 Patients with DHF have, on average, increased relative wall
thickness and an increased mass-to-volume ratio,44 but these findings
often occur in the setting of normal LV mass. Thus, LVH is not
invariably present in DHF, in which the cardiac phenotype is variable.
There is some evidence that the prevalence of LVH may be higher in
African American DHF patients.
Doppler Echocardiographic Assessment of Diastolic Function and
Filling Pressures
Early studies focused on the transmitral flow velocity profile.
Decreases in the ratio of early to late diastolic filling (E/A), increases in
the deceleration time (DT) of the early diastolic filling velocity profile,
or increases in the isovolumic relaxation time (IVRT) indicate impaired
relaxation. However, in the presence of impaired relaxation, increases in
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filling pressure progressively modify the transmitral gradient and mitral
inflow pattern. A comprehensive Doppler assessment is used to
determine diastolic function and filling pressures. Patients studied at
various times during their presentation (e.g., acutely decompensated,
after initial treatment of an acute decompensation episode, or as stable
outpatients) will display a spectrum of filling patterns, including
abnormal relaxation and pseudonormal or restrictive patterns. Such a
spectrum has also been reported in patients with HF with a depressed EF
and reflects the potent effect of filling pressures, blood pressure, and
their interaction with underlying diastolic dysfunction on the Doppler
patterns.
Left Atrial Enlargement
Increases in left atrial dimension or volume is commonly, if not
almost uniformly, present in patients with DHF46
Pulmonary Hypertension
Just as chronic pulmonary venous hypertension leads to
pulmonary arterial hypertension in HF with depressed systolic function,
the same can occur in DHF, and an elevated tricuspid regurgitant
velocity indicative of pulmonary hypertension is common in DHF.
Chronic pulmonary venous hypertension in HF has a direct
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hemodynamic effect on pulmonary pressure and causes reactive
pulmonary hypertension, which can be slow to resolve after
normalization of LV filling pressures. With time, chronic pulmonary
venous hypertension causes pulmonary vascular remodeling (congestive
pulmonary vasculopathy) and irreversible pulmonary hypertension.
These changes are well described in HF with a reduced EF and mitral
valvular disease but can occur in DHF as well. The prevalence of
significant pulmonary hypertension in DHF is as high as 50 percent.42
Other Doppler Echocardiographic Findings
Regional wall motion abnormalities (with preserved EF) and right
ventricular dilation, either because of ischemic disease or pulmonary
hypertension, can also be present at echocardiography in patients with
DHF.[26] Additional important negative findings to be considered at
echocardiography include the absence of valvular disease important
enough to cause the HF symptoms, pericardial tamponade or
constriction, or the presence of congenital heart diseases such as atrial
septal defect or other more extensive structural abnormalities.
Proposed progression of diastolic function abnormalities as
assessed with comprehensive Doppler echocardiography, with
correlation of invasively measured diastolic properties.
A comprehensive Doppler assessment can yield useful information
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regarding relaxation, filling pressures, and (indirectly) diastolic stiffness
in most patients but requires careful data acquisition and informed
interpretation.
Natriuretic peptides
BNP is produced in the myocardium in response to an increase in
ventricular diastolic stretch, and its secretion results in natriuresis,
vasodilatation, and improved ventricular relaxation. In patients with
DHF, BNP values correlate with indices that evaluate the early and late
LV diastolic relaxation. High values have been observed in patients with
late or abnormal relaxation. Since BNP levels may be influenced by
different conditions (sepsis, liver failure, kidney failure, COPD,
obesity), high BNP values do not provide sufficient evidence for the
diagnosis of diastolic dysfunction, requiring additional tests for the
diagnosis of DHF, a high positive predictive value was determined when
the  BNP  cut-off  point  was  chosen  (200  pg/ml).  For  the  exclusion  of
HFNEF, a high negative predictive value was determined for the choice
of the BNP cut-off point (<100 pg/ml)5.
Therefore, natriuretic peptides are mainly recommended for
exclusion, and not for diagnosis of DHF. Since BNP alone does not
provide evidence for the diagnosis of DHF, it should always be used
with other non-invasive tests.
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Exercise Testing
Cardiopulmonary exercise testing (CPET) is useful in the
diagnostic evaluation of exercise intolerance of unclear cause and thus,
in select patients with suspected DHF in whom concern over pulmonary
limitations also exist, CPET may play a role in the diagnostic
evaluation. Objective measures of exercise tolerance are similarly
impaired in HF (of similar clinical severity) with reduced and preserved
EF.[12] Although the prognostic features of metabolic stress testing are
less  well  described  and  less  relevant  in  the  DHF  population,  few  of
whom are considered for cardiac transplantation, standard exercise
stress testing without metabolic measurements may be useful in the
evaluation and management of patients with DHF. Exaggerated
hypertensive responses to exercise causes load-dependent diastolic
dysfunction and recognition, and treatment of exercise-induced
hypertension is important in the treatment of DHF. Importantly, stress
testing also allows assessment of the heart rate response to exercise.
Whereas past recommendations have focused on the potential use of
negative chronotropic agents to allow a longer diastolic filling period in
patients with impaired relaxation, recent studies have suggested that
chronotropic incompetence is also relatively common (higher than 20
percent) in patients with DHF(although not more common than in HF
with a reduced EF), even in the absence of beta blocker therapy.
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DIAGNOSTIC CRITERIA FOR DIASTOLIC HEART FAILURE
Previous and ongoing studies
Vasan  et  al.  reviewed  31  studies  of  CHF  with  normal  LV
systolicfunction published between 1970 and 1995,mostly clinical
comparative studies, mostly hospital based. Apart from a striking lack of
uniformity in the criteria for congestive heart failure that were applied in
these studies, they found that only three of 31 studies provided details
regarding the exclusion of alternative explanations for dyspnea, which is
essential, since the signs and symptoms of congestive heart failure are
nonspecific. In addition, only six of 31 studies assessed ventricular
diastolic function in a satisfactory manner, whereas in most studies the
mere presence of a normal LV systolic function was considered
synonymous with diastolic heart failure. In these studies, a LV ejection
fraction  above  a  certain  cut-off  point  (e.g.  45%)  was  used  as  inclusion
criterion. Vasan et al. concluded, that the lack of consensus and
subsequent heterogeneity in previous studies emphasize the need for
prospective and uniform evaluation of patients with diastolic heart
failure to better characterize epidemiology and natural history, as well as
optimal treatment. In two ongoing studies of ACE inhibitors in diastolic
heart failure, the investigators have already provided specified reports of
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the in- and exclusion criteria, which will be applied to patients to allow
for participation. In the PEP-CHF study, perindopril will be compared to
placebo in elderly patients with chronic heart failure in the absence of
any major LV systolic dysfunction47.
The investigators aim to recruit one thousand patients over the
age of 70 years into their study, and will follow-up on these patients for
at  least  one  year.  Primary  end-point  of  the  study  is  the  time  to  first
occurrence of a combined end-point of total mortality and unplanned
heart failure related hospital admission. The latter includes
hospitalization due to an increase in severity of the heart failure signs or
symptoms, hospitalization for declining renal function or acute
myocardial ischemic events or arrhythmias that are associated with
worsening of heart failure, as well as admissions because of other
problems, such as infections, that lead to an exacerbation of congestive
heart failure. Secondary outcome measures in this study include death,
an increase in diuretic treatment of over 40 mg furosemide per day (or
equivalent) or new initiation of combination therapy with thiazide
diuretics.
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PRIMARY DIASTOLIC HEART FAILURE CRITERIA PROPOSED
BY EUROPEAN STUDY GROUP ON DIASTOLIC HEART FAILURE
1.  Presence of signs or symptoms of congestive heart failure
Exertional dyspnoea if possible objectivated by reduced peak
exercise oxygen consumption (< 25 ml/kg/min), orthopnoea, gallop
sounds, pulmonary edema
2.  Presence of normal or mildly reduced left ventricular (LV)
systolic function
Baseline LV ejection fraction >/=45% in the presence of LV end-
diastolic internal dimension index of < 3.2 cm/m2 or LV end-diastolic
volume index <102 ml/m2
3.  Evidence of abnormal LV relaxation, filling, diastolic
distensibility and stiffness
(a) Slow IVRT
LV dp/dt(min)<1100 mmHg/s and/or
IVRT (<30yrs)>92 ms, IVRT(30-50yrs)>100 ms,
IVRT(>50yr)>105 ms and/or t>48 ms and/or
(b) Slow early ventricular filling  PFR<160 ml/s/m2 and/or PFR
(<30y)< 2.0 EDV/s, PFR(30-50yrs)< 1.8 EDV/s, PFR(>50yrs)<1.6
EDV/s and/or  E/A (<50yrs)< 1.0 and DT(<50yr)>220 ms, E/A
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(>50yr)< 0.5 and DT(>50yr)>280 ms and/or S/D(<50yrs)>1.5,
S/D(>50yr)>2.5 and/or
(c) Reduced LV diastolic distensibility
     LVEDP>16 mmHg or
     Mean PCWP>12 mmHg and/or
     PV A flow>35 cm/s and/or
     PV A flow velocity duration>MV A flow velocity duration+30
ms    And/or    A/H>0.20
(d) Increased LV chamber or muscle stiffness
             b>0.27 and/or     b’>16
LV, left ventricular; IVRT, iso-volumic relaxation time; PFR,
peak filling rate; DT, deceleration time; S/D, ratio of pulmonary vein
systolic and diastolic flow velocities; EDV, end-diastolic volume; EDP,
end-diastolic pressure; PCWP, pulmonary capillary wedge pressure; PV
A flow, pulmonary venous atrial flow; MV A flow, mitral atrial flow;
A/H,  ratio  of  atrial  wave  to  total  signal  wave  excurion  on  the  apex
cardiogram; b, constant of LV chamber stiffness; b9, constant of muscle
stiffness. in symptom score, quality of life or NYHA heart failure score.
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              The PEP-CHF study requires clinical and echocardiographic
evidence of cardiac dysfunction rather than the mere absence of systolic
dysfunction for inclusion. A first report on the ongoing screening
process reports of considerable numbers of patients excluded because of
comorbidity and significant systolic dysfunction. This suggests, that the
use of positive echo criteria for diastolic dysfunction may lead to a
lower proportion of patients with a diagnosis of diastolicheart failure
than in previously reported series. However, as the research group
comments, the need for studies of the elderly heart failure population
with its comorbidity and functional impairments remains irrefutable48.
              The Hong Kong Diastolic Heart Failure study has already
started in May 1999, and includes patients who have clinical evidence of
heart failure documented by typical symptoms and signs, and
radiological evidence of pulmonary venous congestion, combined with a
LV ejection fraction over 45% as measured by echocardiography49.
Patients are randomized to diuretics alone, diuretics plus ramipril, or
diuretics plus irbesartan. The investigators also plan to recruit
approximately 1000 patients, 300 in each group. The primary end-point
is again a combination of mortality and episodes of hospitalization, with
secondary end-points being quality of life and exercise capacity as
measured by a validated questionnaire and 6-min walking tests,
respectively.
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DIASTOLIC HEART FAILURE CRITERIA PROPOSAL
1.  Definite diastolic heart failure is
(a) Definite evidence of congestive heart failure
      Clinical symptoms and signs, supporting chest X-ray, typical
clinical  response to diuretics With or without elevated LV filling
pressure or low cardiac index and
(b) Objective evidence of normal LV systolic function in
proximity of event LV EF>/=50% within 72 h of event and
c) Objective evidence of LV diastolic dysfunction
Abnormal LV relaxation/filling/distensibility indices on catheterization
2.  Probable diastolic heart failure is
(a) As definite and
(b) As definite and
(c) No conclusive information on LV diastolic function Patients
fullfilling criteria 1 and 2 are accepted as having probable diastolic heart
failure, provided that mitral valve disease, corpulmonale, primary
volume overload and non-cardiac causes are excluded.
3.  Possible diastolic heart failure is
(a) As definite and
(b) LV EF>/=50%, not measured within 72 h of event and
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(c) No conclusive information on LV diastolic function
  The diagnostic probability for diastolic heart failure may
increase if the clinical setting is typical for the presence of LV diastolic
dysfunction. According to the authors, this would  apply to a patient
with a markedly elevated blood pressure during congestion, or a patient
with moderate concentric hypertrophy without concomitant wall motion
abnormalities on echocardiography, or if tachy-arrhythmia such as atrial
fibrillation accompany congestive heart failure, or if congestive heart
failure occurs after the administration of small amounts of intravenous
fluid in a patient with normal LV ejection fraction. Diastolic heart
failure may also become more likely if the heart failure improves with
treatment  directed at the underlying cause of diastolic dysfunction, such
as lowering blood pressure, controlling a rapid heart rate, or restoration
of atrioventricular synchrony.
TREATMENT
               In general, the management of DHF has two objectives. The
first is to treat the presenting syndrome of HF—relieve venous
congestion and eliminate precipitating factors. The second is to reverse
the factors responsible for diastolic dysfunction or other perturbations
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that lead to DHF. Both nonpharmacological and pharmacological
strategies may be used to achieve these objectives. Present treatment
strategies for DHF are largely based on assumptions regarding its
pathophysiological mechanisms and on extrapolations from proven
strategies used in HF with a reduced EF.
Goals for Treating Diastolic Heart Failure
Treat precipitating factors and underlying disease.
Prevent and treat hypertension and ischemic heart disease.
Surgically remove diseased pericardium.
Improve left ventricular relaxation.
    ACE inhibitors
    Calcium channel blockers
Regress left ventricular hypertrophy (decrease wall thickness and
remove excess collagen).
ACE inhibitors and ARBs
Aldosterone antagonists
Beta blockers
Calcium channel blockers
Maintain atrioventricular synchrony by managing tachycardia
(tachyarrhythmia).
Beta blockers (preferred)
Calcium channel blockers (second-line agents)
45
Digoxin (controversial)
Atrioventricular node ablation (rare cases)
Optimize circulating volume (hemodynamics).
ACE inhibitors
Aldosterone antagonists (theoretical benefit)
Salt and water restriction
      Diuresis, dialysis, or plasmapheresis
Improve survival.
Beta blockers
      ACE inhibitors
Prevent relapse by intensifying outpatient follow-up.
Control blood pressure.
Dietary counseling (sodium)
Monitoring volume status (daily weights and diuretic adjustment)
Institute exercise program.
Nonpharmacological Therapy
           General measures that may be used in the management of
patients with chronic DHF are not different from those pursued in
patients with HF with a reduced EF. They include daily monitoring of
weight, attention to diet and life style, patient education, and close
medical follow-up. In patients with DHF, aggressive control of
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hypertension, tachycardia, and other potential precipitants for HF
decompensation should be emphasized.52Although there are no adequate
clinical trials with appropriate outcome endpoints, such as increased
longevity, decreased symptoms, or improved quality of life, to prove the
benefits of exercise training in patients with DHF definitively, several
clinical and experimental studies have suggested that exercise training
would be beneficial for such patients. [11] [12] [27]
Medical and Surgical Therapy
In contrast to the treatment of HF with reduced EF, information to
guide the pharmacological therapy of patients with DHF are lacking.
CLINICAL STUDIES
Small controlled studies have been performed using various
standard HF drugs in patients with DHF. The drugs used have included
ACE inhibitors, angiotensin receptor antagonists, beta blockers, and
calcium channel blockers. These trials have, however, been small or
have produced inconclusive results.[53]
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RANDOMIZED CONTROLLED CLINICAL TRIALS
The Digitalis Investigators Group (DIG) Trial included a small
subgroup of patients with DHF. In the DHF group, digoxin did not alter
the primary endpoint of HF hospitalization or cardiovascular mortality
but did reduce HF hospitalizations.[54]
In the CHARM-Preserved Trial,[55] HF patients with an EF higher
than 40 percent were randomized to candesartan (an angiotensin
receptor antagonist) or placebo in addition to standard therapy. Fewer
patients in the candesartan group than in the placebo group reached the
primary endpoint of cardiovascular death or HF hospitalization, a
finding that reached statistical significance only after adjusting for
nonsignificant differences in baseline characteristics
In  the  PEP-CHF  trial,  patients  older  than  70  years  with  chronic
HF and normal or near-normal EF were randomized to perindopril (an
ACE inhibitor) or placebo.[56] The primary endpoint was a composite of
all-cause mortality or unplanned HF-related hospitalization. Both
enrollment and event rates were lower than anticipated and there was a
high rate of cessation of blinded therapy, with crossover to open-label
ACE inhibitor use in both groups. These factors limited the strength of
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the study, which did not show significant reduction in the primary
endpoint. Some trends toward benefit, primarily driven by reduction in
HF-related hospitalizations, were observed at 1 year, when crossover
therapy rates were lower.
The SENIORS trial tested the effect of the beta1-selective blocker
nebivolol in patients with HF.[57] Nebivolol also has vasodilator
properties thought to be related to its effects on nitric oxide release. This
trial was not restricted to those with normal EF. There was a modest but
significant reduction in the primary endpoint of all-cause mortality or
cardiovascular hospitalizations which was driven primarily by the effect
on hospitalizations. Prespecified subgroup analysis in patients with
EF > vs < 35 percent did not detect any trends toward reduced benefit in
those with higher EF. Unfortunately, there were very few patients with
EF > 50 percent in the trial.
Ongoing clinical trials in DHF are testing the efficacy of the
endothelin antagonist, sitaxsentan sodium, irbesartan (I-PRESERVE
trial), combinations of diuretics, ramipril, and irbesartan (Hong Kong
Diastolic Heart Failure study), aldosterone antagonists (TOPCAT trial),
and nesiritide.
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CURRENT THERAPEUTIC RECOMMENDATIONS
It is important to treat other contributing comorbidities and risk
factors aggressively, such as diabetes, hyperlipidemia, renal
dysfunction, and renal vascular disease. One retrospective study has
shown that statin use, but not the use of beta blockers, ACE inhibitors,
or calcium channel blockers, is associated with improved survival in
patients with DHF.[58] Until more clinical trials are performed in patients
with DHF, the empirical nature of therapeutic recommendations and
their uncertain benefit must be recognized.
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Recommendations for Treatment of Patients with Heart Failure
with Normal Ejection Fraction
Class Recommendation
Level of
Evidence
I Physicians should control systolic and diastolic
hypertension, in accordance with published guidelines.
A
I Physicians should control ventricular rate in patients
with atrial fibrillation.
C
I Physicians should use diuretics to control pulmonary
congestion and peripheral edema.
C
IIa Coronary revascularization is reasonable in patients
with coronary artery disease in whom symptomatic or
demonstrable myocardial ischemia is judged to be
having an adverse effect on cardiac function.
C
IIa Restoration and maintenance of sinus rhythm in
patients with atrial fibrillation might be useful to
improve symptoms.
C
IIb The use of digitalis to minimize symptoms of heart
failure is not well established.
C
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RESULTS AND OBSERVATION
PERCENTAGE OF DIASTOLIC HEART FAILURE IN
ELDERLY CONGESTIVE CARDIAC FAILURE
TOTAL
POPULATION
DIASTOLIC HF SYSTOLIC HF
90 42(46.66%) 48(53.34%)
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AGE DISTRIBUTION
AGE GROUP DIASTOLIC HF SYSTOLIC HF
60-65 5(11.90%) 8(16.66%)
66-70 6(14.28%) 10(20.83%)
71-75 8(19.04%) 12(25%)
76-80 11(26.19%) 11(22.91%)
>80 12(28.57%) 7(14.58%)
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 SEX DISTRIBUTION
STUDY
POPULATION
DHF SHF TOTAL
MALE 12(28.97%) 33(68.75%) 45
FEMALE 30(71.42%) 15(31.25%) 45
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DIASTOLIC HEART FAILURE WITH HYPERTENSION
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 36 8(19.04%) 28(66.6%) 85.7%
SHF 35 20(41.6%) 15(31.25%) 72.9%
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DIASTOLIC HEART FAILURE WITH CORONARY ARTERY
DISEASE
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 28 12(28.57%) 16(38.09%) 59.52%
SHF 35 23(47.91%) 12(25%) 72.91%
CAD-DHF CAD-SHF
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DIASTOLIC HEART FAILURE WITH DIABETES MELLITUS
STUDY
POPULATION
TOTAL
NO DM
MALE FEMALE PERCENTAGE
DHF 25 10(23.80%) 15(35.71%) 59.52%
SHF 26 16(33.33%) 10(20.83%) 54.16%
DM-DHF DM-SHF
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DIASTOLIC HEART FAILURE WITH HYPERLIPEDIMIA
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 26 10(23.80%) 16(38.09%) 61.90%
SHF 31 18(37.5%) 13(27.08%) 64.58%
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DIASTOLIC HEART FAILURE WITH OBESITY
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 18 6(14.28%) 12(28.57%) 42.85%
SHF 10 4(8.33%) 6(12.5%) 20.83%
59
DIASTLIC HEART FAILURE WITH ATRIAL FIBRILLATION
STUDY
POPULATION
TOTAL
NO
MALE FEMALE PERCENTAGE
DHF 10 6(14.28%) 4(9.52%) 23%
SHF 8 5(10.41%) 3(6.25%) 16.66%
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DIASTOLIC HEART FAILURE WITH SMOKING
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 12 10(23.80%) 2
(4.76%)
28.57%
SHF 16 16(33.33%) 0(0%) 33.33%
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DIASTOLIC HEART FAILURE WITH CHRONIC KIDNEY
DISEASE
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 6 2
(4.98%)
4 (9.52%) 14.28%
SHF 8 7
(14.58%)
1( 2.08%) 16.66%
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DIASTOLIC HEART FAILURE WITH HYPOTHYROIDISM
STUDY
POPULATION
TOTAL MALE FEMALE PERCENTAGE
DHF 3 2(4.76%) 1(2.38%) 7.14%
SHF 2 1(2.08%) 1(2.08%) 4.16%
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CLINICAL MANIFESTATIONS
S.NO CLINICAL PRESENTATION NO PERCENTAGE
1 EXERTIONAL DYSPNEA 42 100%
2 PND 38 90.47%
3 ORTHOPNEA 36 85.71%
4 NOCTORNAL COUGH 30 71.42%
5 RALES 40 95.23%
6 ANKLE EDEMA 34 80.95%
7 PLEURAL EFFUSION 10 23.80%
8 HEPATOMEGALY 6 14.28%
9 TACHYCARDIA 18 42.85%
10 JUGULAR VENOUS PULSE 8 19.04%
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DISCUSSION
? In this study 90 elderly people with congestive cardiac failure
from general hospital were studied for prevalence of Diastolic
Heart Failure with symptoms and Echocardiographic analysis. Of
this 90 persons 45 were male,45 were female
? The overall prevalence of DHF among the elderly congestive
cardiac  patients  was  found  to  be  46%  Prevalence  of  DHF
increasing with age was noted 11.9% of DHF patients were found
to be in the age group of60-65 yrs,14.28% among 65-70yrs,
19.04%in 71-75 yrs,26.19%in 76-80,28.57% in age group above
80yrs. Although cardiovascular disease may contribute to
diastolic dysfunction in older people, study shown  that diastolic
function deteriorates with normal aging. The speed of LV
relaxation declines with age in men and women, even in the
absence of cardiovascular disease. It also appears that vascular,
LV systolic, and LV diastolic stiffness increase with aging.
Increases in vascular stiffness have been shown to be related to
effort intolerance in patients with DHF. Structural cardiac
changes with aging (e.g., increased cardiomyocyte size, increased
apoptosis with decreased myocyte number, altered growth factor
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regulation, focal collagen deposition) and functional changes at
the cellular level involving blunted beta-adrenergic
responsiveness, excitation-contraction coupling, and altered
calcium handling proteins may contribute to diastolic dysfunction
with normal aging
? Prevalence of  DHF in the male population with CHF was found
to be 37.7% whereas in female population was found to be 66.6%
Along with age, female gender is a potent risk factor for DHF,.
Indeed, there appears to be important age-gender interactions,
such that the prevalence of DHF increases more sharply with age
in women than the prevalence of HF with a reduced EF. The
reasons for the female predominance in DHF are not entirely
clear, but women have higher vascular and LV systolic and
diastolic stiffness than men, and vascular and ventricular stiffness
increases more dramatically with age in women..
? Among patients with DHF major association was found to be with
Systemic hypertension.85.7% of patients with DHF were found to
be hypertensive and 72.9% of patients with SHF had
hypertension. Chronically increased blood pressure is an
important stimulus for cardiac structural remodeling and
functional changes. The resultant hypertensive heart disease is
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characterized by LV hypertrophy (LVH), increasing vascular and
ventricular systolic stiffness, impaired relaxation, and increased
diastolic stiffness, all factors linked to the pathogenesis of DHF.
In the presence of hypertensive heart disease, ischemia produces
exaggerated increases in filling pressures, and hypertensive and
ischemic heart disease are often present in combination inpatients
with DHF.
? In patients with DHF 66.6% was associated with coronary artery
disease whereas 72.9% of patients with SHF had coronary artery
disease. prevalence of coronary artery disease or myocardial
ischemia in patients with DHF varies widely. Although acute
ischemia is known to cause diastolic dysfunction, the role of
coronary artery disease and ischemia in contributing to chronic
diastolic dysfunction and symptoms in patients with DHF remains
speculative. Despite uncertainty regarding the role of ischemia in
the pathophysiology of DHF and a lack of data documenting that
revascularization improves outcomes in patients with DHF, HF
management guidelines recommend revascularization in those
DHF patients in whom “ischemia is felt to contribute to diastolic
dysfunction.”
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? 59.52% of patients with DHF had diabetes and 54.16% with SHF
were diabetic. the prevalence of diabetes is similar in patients
with HF and reduced or preserved EF, suggesting that diabetes
contributes to the pathophysiology of both forms of HF. Although
diabetes predisposes to coronary artery disease, renal dysfunction,
and hypertension, numerous direct effects of diabetes and
hyperglycemia on myocardial structure and function have been
described
? 61.9%of patients with DHF had high lipid levels and 64.58% of
SHF patients had hyperlipidemia.
? In  23%  of  patients  with  DHF  atrial  fibrillation  was  noticed  and
16.66% of patients with SHF had associated AF. Atrial fibrillation
is recognized as a frequent precipitant of acute decompensation in
patients with DHF. Potential mechanisms responsible for this
frequent presentation are discussed more fully later. Whereas
atrial fibrillation may cause decompensated HF in patients with
diastolic dysfunction, diastolic dysfunction (in the absence of HF)
is also a risk factor for atrial fibrillation. Thus, diastolic
dysfunction, atrial fibrillation, and DHF are common and related
conditions that probably share common pathogenic mechanisms
in the elderly.
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? 42.85% of patients with DHF fell into the obese category and
20.83% with SHF were found to be obese. the prevalence of
diastolic dysfunction is increased in obese persons. Increased
adiposity not only imposes an adverse hemodynamic load on the
heart but is also a source of a large number of biologically active
peptide and nonpeptide mediators, many linked to chronic
inflammation by various pathways. Increased body mass index
(BMI) is a risk factor for hypertension, diabetes mellitus,
coronary artery disease, and atrial fibrillation, all of which are
associated with DHF.
? 14.28% of patients with DHF had associated chronic renal disease
and 16.66% of SHF patients had renal disease.
? 47.61% patients with DHF had smoking as risk factor and 33.33%
of SHF patients were found to smoke.
? 7.14% of DHF patients were hypothyroid and 4.16% of patients
with SHF had associated hypothyroidism.
? The most common presentation of patients with DHF was found
to be exertional dyspnea and the most common finding on
examination of patients with DHF was found to be basal crackles
and ankle edema.
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CONCLUSION
? 40- 50% of  elderly  with CHF  have DHF.
? The prevalence of DHF has increased with age and appears to be
quite common in elderly women with hypertension
? T he diagnosis of DHF is generally based on typical symptoms
and signs of HF, preserved or normal LVEF, DD and no valvular
abnormalities.
? The goal of therapy is the relief of symptoms, improvement in
quality of life (improved exercise tolerance and reduced hospital
admissions), and prolongation of survival. In   the elderly, relief
of symptoms and improvement of quality of life are crucial
? The outcomes of pharmacological therapy in patients with DHF
are frequently neutral in clinical trials. Further trials are necessary
to outline a  specific line of therapy.
? Prognosis of DHF is as poor as that of systolic failure and if left
undetected the mortality is as high as in systolic heart failure.
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2 65 F Y Y N N N Y Y N N 200 34 1.1 78 11 76 148/90 PRWP N 56 2 DHF
3 64 F Y Y N N N Y N N N 184 29 1.3 88 12 78 150/88 LAD CM 70 1 DHF
4 62 F Y Y N N N Y N N N 163 28 0.9 80 13.5 70 150/90 LVH CM 68 1 DHF
5 60 F Y Y N N N Y N N N 174 26 0.8 86 12 68 146/94 LAD PF 65 1 DHF
6 66 M Y Y Y N Y Y Y N N 156 70 2.2 100 14 71 150/98 LVH,LAD CM 64 1 DHF
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48 62 M N Y Y N Y Y Y N N 158 98 3 100 11 72 120/80 WNL N 35 N SHF
49 64 M N Y Y N Y Y Y Y N 198 70 2.6 86 13 70 110/70 WNL N 40 N SHF
50 65 M N Y Y N Y Y Y N N 169 86 2.4 86 12 72 120/84 WNL N 42 N SHF
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65 74 M Y Y Y N N N Y N N 176 37 0.9 72 13 70 120/86 WNL N 28 1 SHF
66 72 M Y Y Y N N N Y N N 198 27 0.8 79 11 74 140/80 WNL N 30 N SHF
67 71 M Y Y Y N N N Y N Y 186 26 0.8 140 12.5 72 136/40 WNL N 29 N SHF
68 72 M Y Y Y N N N Y N Y 196 25 0.8 136 11 70 124/80 WNL N 36 N SHF
69 73 M Y N Y N N N N N Y 110 32 1 132 10 69 134/90 WNL N 40 N SHF
70 74 M Y N Y N N N N N Y 74 31 1.1 150 12 72 134/86 WNL N 42 N SHF
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84 81 M Y N N N N N N N Y 108 25 0.8 134 12 80 160/90 LVH CM 31 N SHF
85 85 M Y N N Y N N N N Y 106 21 0.8 130 13 76 156/88 LAD N 36 N SHF
86 86 M Y N N Y N N N N Y 112 28 0.9 168 12 72 184/90 LVH CM 30 N SHF
87 83 M Y N N Y N N N N Y 116 22 0.8 178 13 75 168/90 LVH CM 35 N SHF
88 82 M Y N N Y N N N N Y 98 28 0.9 168 12 73 144/88 LAD N 31 N SHF
89 81 M Y N N Y N N N N Y 118 32 1 142 11.8 70 134/86 PRWP PF 28 N SHF
90 83 M N Y Y N Y Y N Y N 218 90 3 132 11.4 90 120/80 WNL N 30 N SHF

